In our study, the findings associated with the clinical outcomes related to the TTD, TTP, TTNT-D, and ORR favoring selpercatinib versus standard therapies or MKIs also support selpercatinib’s role as the frontline therapy for RET-activated NSCLC and MTC. This evidence concerns the gene RET and medullary thyroid gland carcinoma.